Member Info for Num4

Soo Roivant, a very interesting read, https://www.biopharmadive.com/news/roivant-montes-archimedes-spac-merger/599446/

At a glance it appears they have processes to produce best in class molecules using various methods, but the goal is what they call TPP, Target Product Profile.

This is a great read..https://discovery.roivant.com/drug-discovery/best-in-class-small-molecules/

It feels very much like what Sareum do, but in a more in-house system, if Sareum need supercomputer data, we outsource...

If you also look at the their main platform, QUAISAR, note the SAR in the name, it stands for Structure-Activity Relationships. See this:
https://discovery.roivant.com/quaisar-platform/

The origins of Sareum, also incorporate SAR, and yes it's refereeing to the same thing.

Not sure where I'm going with this, more a ramble after some interesting similarities, except of course the valuations.

What is interesting is that Pfizer have chosen them as a partner, thinking about their expertise and the problems with tyk2/jak1 I would say they are tasked with making a tyk2/jak1 more target specific as it's currently not good enough - if it was there wouldn't have been a delay by Pfizer.

We are at the end of that process really, and time to see the results in humans.

Overall this partnership between the two means tyk2/jak1 just got another player, and from memory it's not allosteric (I actually don't think they ever announced).

The value here is just primed and ready to explode, GSK may well be looking at Sareum, there is plenty to like, as we all know.
It's quite amazing when you think what these 2 guys have done when you compare that to what Roivant is to produce something similar, now - who will be the best in class... That's the question, the beauty of these molecules is that there are plenty of targets with different profiles, so one compound won't fit all disease.
Take care all.

https://www.fiercebiotech.com/biotech/novartis-plots-precision-attack-sickle-cell-paying-50m-and-putting-14b-biobucks-form-vivo

Creative deal, something like this for TYK2 assets is perfect, give them skin in the game, give them options, guarantee some big milestones and take an upfront payment, not forgetting royalties.
Get a major name and it's £10 a share.

Tim has said before that they are in constant communication with industry pharma's, on an international level. Look at the Investor Meet Company sessions and the written Q&As. Options or no options, I don't think that matters with Sareum, they have been NEDs for a while, and I don't get the feeling they are trying to milk this, and to be fair to Tim, he has always maintained his stance on building shareholder value, as confusing as that may sound look at the trend of late.
But his long-term goals have stood the test of time and consistent shareholder approval of the business AGM and EGM statements.
There is no activist investor trying to rock the boat as an investment with Sareum is obviously a solid investment in the long run, some of us have been on the marathon with the injuries and scars to show for it.
As I said this morning, the lack of any RNS is not the normal considering we should have so much data available on SDC-1801, Investigational Brochure must be nearing completion.
Nimbus still progressing their TYK2 but we are yet to show our hand and enter the arena. When we do, are we doing it as a 2 man company? I hope not.

It's interesting the complete radio silence from the company, one of the last RNS's noting the GSK takeover including the part owned asset SRA737 then nothing.
Will the June trading update happen or are we waiting until August?
Either way, the fall in SP is doing them no favours with shareholders and the HNWI's. Next update is becoming critical.

We've been told very recently that we are on track for H2 22 for submitting the CTA, we are now in H2. We have the trading update due before the end of the month for the financial year ending 30th June 2022. So it is my belief we will see an update before 30th June.
The capsule formulation update will be welcome and it may not be finished but as long as it's still on track that's all we can ask for. They can make the CTA without the capsule being ready, I do expect the trial to start this year and look forward to reading the finer details. We have been consulting with specialists in trial design for a long time now, this might just be something very different, especially considering the COVID application which we've already been told will run side by side.
Once we start to get going and the GSK links start to be in the limelight, then a full cash offer for our share of SRA737 will be touted, rumours will be ripe and rightly so. End game should be approaching for Sareum because don't forget their overall strategy is to out-license pre-clincial or early clinical - once we have initial safety data for SDC-1801, which won't take long then it'll be sold, IMO. The most exciting time in the history of Sareum is upon us, 13years of investments coming to fruition. ~20years work for Tim and John comes down to the next few months.

If that's how you start your Mondays Utah I feel sorry for you.

Perhaps try the investor meet company sessions, no indications will be mentioned in our in human safety study, then the idea is to license it. The longer the interested parties wait the more we demand and the more interest we accumulate, hence the balance between big deals and early license, as we are repeatedly told.
Can we just fast forward a year...thanks...

It's not for all of the above, it's for none of the above. Keep reading

Financial year end for Sareum is end of June, last year we had a trading update end of May. Still nothing to report apart from a tweet of how well BMS are pushing ahead with their TYK2.
John has been at the Jak development forum but not presenting, just attending. Time for them to show their hand this month.

Ahfam, the 2 patents below have both been terminated before grant.
Use this link to confirm with the application number: https://www.ipo.gov.uk/p-ipsum.htm
28 November 2018
(Journal 6758) GB1816369.1 Applicant: Sareum Limited
Title: Pharmaceutical compounds
Date Lodged: 8 October 2018
20 May 2020
(Journal 6835) GB2005114.0 Applicant: Sareum Limited
Title: Crystalline Forms of a Pharmaceutical Compound
Date Lodged: 7 April 2020

Had a refresh of our CHK1 molecule and it looks like the industry is still producing research based on utilizing a CHK1 inhibitor:
https://www.sciencedaily.com/releases/2022/04/220407101045.htm
"Their findings present the biological and therapeutic relevance of Chk1 inhibition in targeting DDR and genomic instability, both of which are characteristic traits of high-risk patients with co-occurrence of the two chromosomal abnormalities. More importantly, discovering the Achilles' heel of this disease has opened doors for more effective and novel treatment modalities to address an unmet medical need of myeloma."

They used AZD7762 for the above but this is no longer in development by Astra; "Unfortunately, the clinical development of AZD7762 was hampered by drug-related cardiac toxicity, which was dose limiting in some cases"
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/prexasertib

WEE1 with CHK1: A long time link here and further evidence of this combo:
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off

Prexasertib the last remaining competitor in CHK1 discontinued in 2019:
https://www.fiercebiotech.com/biotech/lilly-dumps-phase-2-cancer-drugs-survived-previous-cull

So that leaves our molecule, previously named CCT245737, now named SRA737 as the only remaining CHK1 still active (until we are told otherwise).

The target is good but compounds mentioned above aren't safe enough to proceed to a P3 trial, I think we'll see more trials with our CHK1 and hopefully we are good enough to stay the course. Then it's a monopoly with our CHK1.
So we are betting on the skills of Sareum and ICR in molecule design, so far so good.

No, if it wasn't us it would be someone else. Competition is good, if nobody else was looking at this target then you would be worried.
You also want more treatments, which is what it is all about at the end of the day, some will be better than others in different disease and as time goes by a favourite will emerge but we're getting ahead of ourselves.
The £40k late reported trade explains the drop, mugged right off. Strange.

Come on Celtic you can piece that one together, In September we may have a fully FDA approved TYK2 in the market. Will it come with black box warnings.. hopefully not. This lays the foundation for other tyk2 compounds, none of which differentiate except Sareums.
Big JAK conference in June which a FDA rep is attending and giving speech on what they want to see. Thankfully John Reader is heading over to Boston for this.
Tim just told us and other people looking at Sareum what the market size is. BMS will be approved IMO and if you've not got a TYK2 in your arsenal as a big pharma then they've not been paying attention.

https://news.bms.com/news/details/2021/Bristol-Myers-Squibbs-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency/default.aspx

Huge date for your diary. Will a licensor wait for this date, I think not, license of SDC-1801 done by September, IMO.

Some confusion here SCH. It's not JAK2, that's what everyone wants to avoid, it's a TYK2 only.
SDC-1801 is a selective tyk2/JAK1.
JAK1 is a proven target, tyk2 is becoming another proven target, big date in September for BMS.

Been completed for a while, Tim did make a comment at the time. Payment is on any other trial first dose.
P3 fasttrack is possible with anogential .

https://www.biospace.com/article/-sareum-notes-key-takeaways-from-sierra-oncology-webcast-discussing-positive-preliminary-results-from-phase-1-2-trials-with-sra737-presented-at-asco/

"A very promising signal was observed in anogenital cancer, which represents a tractable opportunity to potentially pursue trials leading to market registration filings given its unmet medical need, particularly in patients for whom initial 1st-line therapy has become ineffective, and substantial potential market opportunity"

"To evaluate further the clinical data in the context of its emerging pipeline, noting that a Phase 2 registration trial for SRA737+LDG in anogenital cancer would cost an estimated $10 million"

GSK probably spend $10million on stationery

Quote from event organiser, "It will be a pre recorded presentation that can be found on the digital platform" https://biotrinityonline.com/
Unfortunately you need to be registered to see them. We'll have to wait on Sareum to publish this.

Now, the positive spin - if we wanted investors then 100% we would have been in person presenting, as we have done in previous years.

They attend BioTrinity every year, a few times they present, that's when we get the RNS, but it's normally on the Bio website as well. If you want to watch Tim speak, then what time is it? When is it?

I don't like this at all, something not right here. They only just updated the events section a few days ago after I emailed Tim directly, they are slow to update it each year but April....
Now an RNS to say we are presenting when according to BioTrinity we aren't, a late addition - why? Someone backed out, unlikely as you book these months in advance normally to get a discount.
I just hope it is not a monumental f up.
Also the fact that the RNS states "updates", so something new is about to come out?
Who knows, but something is not right with this.

According to BioTrinity Sareum are not down for a presentation...unless someone can correct me, I've searched their site and Tim isn't down as a speaker.